In a report released yesterday, Elliot Wilbur from Raymond James maintained a Buy rating on Mylan (MYL). The company’s shares closed last Tuesday at $15.31.
According to TipRanks.com, Wilbur has 0 stars on 0-5 stars ranking scale with an average return of -3.4% and a 41.0% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Amneal Pharmaceuticals, and Flexion Therapeutics.
Mylan has an analyst consensus of Strong Buy, with a price target consensus of $24.00.
See today’s analyst top recommended stocks >>
Mylan’s market cap is currently $7.91B and has a P/E ratio of 29.10. The company has a Price to Book ratio of -0.91.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MYL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Read More on MYL:
